PDF(Sci-hub)
Abstract：
Ramadan is a lunar based month, during which Muslims across the world observe the ritual fast. This provides a challenge not only to the diabetic patient who wishes to observe the fast but also to the health care professional managing his diabetes. The challenge is to use therapies which are effective in maintaining good glycemic control and at the same time have a low propensity to cause hypoglycemia during the several hours of no calorie intake. The GLP-1 analogues are unique agents which are effective in providing glycemic reduction with a very low risk of hypoglycemia and hence find an important place in the management of diabetes during Ramadan. This Consensus Statement describes the pre-Ramadan assessment, planning, prescription and management and monitoring of patients who are on GLP-1 analogues, with or without other antidiabetic therapies.
摘要：
斋月是阴历月,在此期间，世界各地的穆斯林迅速观察仪式。这不仅对希望观察禁食的糖尿病患者而且对管理他的糖尿病的医疗保健专业人员提供了挑战。挑战是使用有效维持良好的血糖控制并且同时在没有卡路里摄入的几个小时期间具有低的引起低血糖的倾向的疗法。GLP-1类似物是独特的药剂,其在低血糖风险非常低的情况下有效地提供血糖降低,并且因此在斋月期间的糖尿病管理中找到重要的位置。这份共识声明描述了斋月前的评估，规划,对服用GLP-1类似物的患者进行处方、管理和监测，有或没有其他抗糖尿病疗法。
